Awareness of the HPV-Cancer Connection, Vaccine Rates Are Lagging
April 18th 2023Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.
Read More
Lutetium 177 PSMA-617 Following Radium-223 Is Active and Safe in mCRPC
February 16th 2023Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.
Read More
Zanubrutinib Delivers Durable Disease Control in Relapsed/Refractory MZL
December 11th 2022Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.
Read More
Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer
September 11th 2022Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.
Read More
Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma
June 5th 2022Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.
Read More
Long-Term Data Show That Tivozanib Continues to Be Superior Vs Sorafenib in mRCC
February 19th 2022Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.
Read More
Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment
December 13th 2021Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.
Read More
Trastuzumab Duocarmazine Shows PFS Benefit in Pretreated, HER2+ Metastatic Breast Cancer
September 19th 2021Vic-trastuzumab duocarmazine yielded an improved progression-free survival over standard physician’s choice chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer.
Read More
Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma
June 8th 2021The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Read More
Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC
June 3rd 2021The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
Read More
Virtual Prehabilitation Improves Activity Level, Exercise Capacity Prior to Lung Cancer Surgery
February 2nd 2021February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.
Read More